Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216577 | 1.00 | RIPK1 (0.39) | RIPK1HCRTR1HCRTR2ALDH1A1GRM5 | |
| SCHEMBL17069039 | 0.84 | HCRTR1 (0.41) | HCRTR1HCRTR2ALDH1A1GRM5TSHR | |
| SCHEMBL12234863 | 0.72 | PREP (0.51) | TSHR | |
| SCHEMBL18815570 | 0.71 | RIPK1 (0.41) | RIPK1HCRTR1HCRTR2ALDH1A1GRM5 | |
| SCHEMBL18815596 | 0.69 | CYP3A4 (0.43) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL24993318 | 0.68 | RIPK1 (0.47) | RIPK1GRM5 | |
| SCHEMBL1576663 | 0.68 | RIPK1 (0.73) | RIPK1 | |
| SCHEMBL23501031 | 0.68 | NTRK1 (0.49) | RIPK1 | |
| SCHEMBL23501030 | 0.68 | NTRK1 (0.49) | RIPK1 | |
| SCHEMBL9682215 | 0.68 | TDP1 (0.62) | RIPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612059-B2 | Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | VICURON PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090149509-A1 | NOVEL PYRROLIDINE BICYCLIC COMPOUNDS AND ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE | VICURON PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1406893-B1 | PYRROLIDINE BICYCLIC COMPOUNDS | VICURON PHARM INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-6987104-B2 | Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | VICURON PHARMACEUTICALS INC. (US) | 2006-01-17 | — | — | US | disclosed |
| US-20050277683-A1 | Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | VICURON HOLDINGS LLC | 2005-12-15 | — | — | US | disclosed |
| EP-1406893-A1 | PYRROLIDINE BICYCLIC COMPOUNDS | Vicuron Pharmaceuticals, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030069223-A1 | Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | VICURON HOLDINGS LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2002102791-A1 | PYRROLIDINE BICYCLIC COMPOUNDS | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069223-A1 | Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | PDF, TPMT, NOD1 | RIPK1 2329/4885HCRTR1 4453/4885HCRTR2 4714/4885 |
| US-20050277683-A1 | Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use | PDF, PNPO, PDXK | RIPK1 1275/4885HCRTR1 4806/4885HCRTR2 4871/4885 |
| US-20090149509-A1 | NOVEL PYRROLIDINE BICYCLIC COMPOUNDS AND ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE | PDF, PNPO, PDXK | RIPK1 1275/4885HCRTR1 4806/4885HCRTR2 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.